On the surface, America looks like an unrivaled success story. Yet beneath the headline numbers lies an economy increasingly dependent on foreign production, hollowed out in critical industries, and unable to provide secure, high-wage work for many of its citizens.
America is finally getting serious about its dangerous dependence on foreign-made generic drugs.
The Trump administration’s section 232 investigation into medical devices and personal protective equipment is a vital step toward ensuring America takes back control over its production and domestic supply of critical medical products.
The hearing continued the committee’s efforts to examine and reduce America’s severely dangerous over-dependence on foreign-manufactured generic drugs and address vulnerabilities in the nation’s pharmaceutical supply chain.
Move seen as a critical step to protect U.S. manufacturing, American jobs, and national security WASHINGTON, D.C. — The Coalition for a Prosperous America (CPA)
The era of global dependency on the CCP is over. For decades, Wall Street, multinational corporations, and globalist institutions helped finance China’s rise at the direct expense of American workers, manufacturers, and national security.
Titled “The New Biotech Cold War: The U.S. Medicine Can’t Afford to Fall Behind China,” the report shows how U.S. biotech – long a pillar of national strength – no longer has a guaranteed edge globally.
Strong enforcement against trade fraud isn’t optional—it’s essential to rebuilding our industrial base and securing long-term prosperity for American communities.
The U.S. Shipbuilding Base has Withered Since the 80s; Latest CPA Report Examines What’s Needed to Bring it Back
The latest Section 232 announcements expand the list of ongoing investigations into imported goods that could be exposed to higher tariffs.
